ReviewCurrent drug discovery technologies2026
Therapeutic Potential of Flavonoids in Diabetes Mellitus Management: Molecular Insights and the Future Directions for Drug Design.
Review in Current drug discovery technologies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cell Reporter-Based Analysis of Anti-Inflammasome Activities of Flavonoids with Distinct Structures.Molecules (Basel, Switzerland) · 2026Article
- Flavonoids: Hemorheological effects and mechanisms of action.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Dietary Polyphenols (Flavonoids) Derived from Plants for Use in Therapeutic Health: Antioxidant Performance, ROS, Molecular Mechanisms, and Bioavailability Limitations.International journal of molecular sciences · 2026Review
- Antioxidant properties of nano-formulated carotenoids and natural phenolic compounds against oxidative stress-induced health diseases.Open research Europe · 2026Review
- Phenolic-derived compounds in osteoporosis-Mechanisms, clinical evidence, and drug delivery: A review.Biomolecules & biomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a prevalent metabolic disorder with a rapidly rising global incidence, presenting a significant burden to healthcare systems worldwide. Flavonoids, a class of naturally occurring polyphenolic compounds, are well-documented for their diverse pharmacological activities, particularly their anti-diabetic and anti-inflammatory effects. These secondary metabolites are commonly found in fruits, vegetables, and fungi and are classified into six main subclasses: flavanols, flavones, flavanones, isoflavones, anthocyanidins, and chalcones. The interplay between hyperglycemia, inflammation, and vascular complications in diabetes is now well recognized. Flavonoids with anti-diabetic properties may help mitigate inflammation by reducing hyperglycemia through various mechanisms. This review explores the antidiabetic potential and molecular mechanisms of citrus flavonoids, drawing on updated evidence from
Indexed as
Identifiers
40457969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.